London: Aspirin, a drug with a history spanning 4,000 years, is now showing promise in reducing cancer risk, findings that are influencing health policies.
According to Ghana Web, aspirin, traditionally used to treat pain, is being recognized for its potential to prevent certain tumors from forming and spreading. This discovery is particularly significant for individuals like Nick James, a British furniture maker who, after genetic testing, discovered he carried a gene for Lynch Syndrome, increasing his cancer risk. James participated in a clinical trial led by Professor John Burn at Newcastle University, testing aspirin's protective effects against cancer.
Depending on the mutation type, Lynch Syndrome patients face a 10-80% lifetime risk of bowel cancer. Encouragingly, after 10 years on aspirin, James remains cancer-free. Burn's trial is part of a growing body of research suggesting aspirin's effectiveness in reducing colorectal cancer spread.
The drug's ancient origins trace back to 4,400-year-old Mesopotamian tablets mentioning willow tree derivatives. In the late 19th century, modern aspirin was developed, leading to its widespread use for cardiovascular disease prevention due to its blood-thinning properties.
Interest in aspirin's anti-cancer properties surged in 2010 when Professor Peter Rothwell of the University of Oxford re-evaluated data on its role in cardiovascular disease and found it also reduced cancer incidence and metastasis. However, proving aspirin's cancer prevention efficacy in the general population is challenging due to the lengthy timelines required for such studies.
Focused research on specific groups, like those with Lynch Syndrome, has yielded significant results. Burn's landmark trial showed that a daily 600mg aspirin dose halved colorectal cancer risk among 861 patients over a decade. A subsequent trial indicated a lower dose (75-100mg) might be equally effective, which is promising given aspirin's potential side effects like stomach ulcers and bleeding.
John Burn's findings have already influenced UK health guidelines, recommending aspirin for Lynch Syndrome patients from age 20 or 35, depending on severity. Meanwhile, Professor Anna Martling's research in Sweden demonstrated aspirin's ability to reduce cancer recurrence post-surgery, leading to changes in Swedish medical practices.
Additional studies are underway to explore aspirin's broader cancer-preventing potential. Professor Ruth Langley is conducting a trial involving participants with various cancer types to assess aspirin's effect on recurrence.
The exact mechanism of aspirin's anti-cancer action is still being studied. It may involve inhibiting enzymes like Cox-2 or enhancing the immune system's ability to target cancer cells. Ongoing research suggests that elements like thromboxane A2, involved in blood clotting, may also play a role.
While some experts advocate for wider aspirin use due to its cardiovascular and potential cancer prevention benefits, others caution against general recommendations due to possible adverse effects. Individuals with conditions like Lynch Syndrome or a history of bowel cancer may benefit from discussing aspirin use with their healthcare providers.
As research advances, aspirin's role in cancer prevention may become clearer, potentially leading to new applications of this ancient drug.